Genotoxicity of anti-tumor necrosis factor therapy in patients with juvenile idiopathic arthritis

Erkan Demirkaya1, Ismet Cok, Emre Durmaz

  • 1Hacettepe University Medical School, Ankara, Turkey. dottore_erkan@yahoo.com

Abstract

Insights

Juvenile idiopathic arthritis (JIA) patients exhibit increased DNA damage and impaired repair. Anti-tumor necrosis factor (anti-TNF) therapy initially improved DNA damage but worsened it over six months, further impairing repair capacity.

Area of Science:

  • Genetics and Molecular Biology
  • Immunology
  • Pediatric Rheumatology

Background:

  • Juvenile idiopathic arthritis (JIA) is an autoimmune condition characterized by inflammation.
  • Anti-tumor necrosis factor (anti-TNF) agents are used to treat JIA, but their impact on DNA integrity is not fully understood.

Purpose of the Study:

  • To evaluate DNA damage and repair capacity in children with JIA.
  • To assess the effects of anti-TNF therapy on DNA damage and repair.

Main Methods:

  • The comet assay was used to analyze DNA damage and repair in peripheral lymphocytes of 16 JIA patients and 16 controls.
  • Samples were collected before and at 15, 90, and 180 days after initiating etanercept (an anti-TNF agent).

Main Results:

  • JIA patients showed higher basal DNA damage and reduced DNA repair capacity compared to controls.
  • Anti-TNF therapy initially decreased DNA tail length (indicating less damage) by day 15.
  • DNA damage increased by day 90 and showed an upward trend thereafter, with further impaired DNA repair observed at 6 months.

Conclusions:

  • JIA is associated with increased DNA damage and deficient DNA repair mechanisms.
  • While anti-TNF therapy may offer initial genoprotective effects, long-term treatment appears to exacerbate DNA damage and impair repair capacity in JIA patients.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...